Competition in the Global HD Therapeutics Market is Non-existent
Global Huntington`s Disease Therapeutics Market to Reach $20 Billion by 2030
The global market for Huntington`s Disease Therapeutics estimated at US$2.2 Billion in the year 2022, is projected to reach a revised size of US$20 Billion by 2030, growing at a CAGR of 31.9% over the analysis period 2022-2030.The U.S. Market is Estimated at $593.2 Million, While China is Forecast to Grow at 40.6% CAGR
The Huntington`s Disease Therapeutics market in the U.S. is estimated at US$593.2 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$5.6 Billion by the year 2030 trailing a CAGR of 40.6% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 25.7% and 28.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 27.2% CAGR.Select Competitors (Total 23 Featured) -
- Alnylam Pharmaceuticals, Inc.
- Evotec AG
- GlaxoSmithKline PLC
- Horizon Therapeutics plc
- Ionis Pharmaceuticals, Inc.
- Raptor Pharmaceutical Corporation
- Sangamo Biosciences, Inc.
- Suven Life Sciences Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Inc.
- Wave Life Sciences Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
CANADA
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
ITALY
UNITED KINGDOM
SPAIN
RUSSIA
REST OF EUROPE
ASIA-PACIFIC
AUSTRALIA
INDIA
SOUTH KOREA
REST OF ASIA-PACIFIC
LATIN AMERICA
ARGENTINA
BRAZIL
MEXICO
REST OF LATIN AMERICA
MIDDLE EAST
IRAN
ISRAEL
SAUDI ARABIA
UNITED ARAB EMIRATES
REST OF MIDDLE EAST
AFRICA
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Alnylam Pharmaceuticals, Inc.
- Evotec AG
- GlaxoSmithKline PLC
- Horizon Therapeutics plc
- Ionis Pharmaceuticals, Inc.
- Raptor Pharmaceutical Corporation
- Sangamo Biosciences, Inc.
- Suven Life Sciences Ltd.
- Teva Pharmaceutical Industries Ltd.
- Vertex Pharmaceuticals Inc.
- Wave Life Sciences Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 172 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2.2 Billion |
Forecasted Market Value ( USD | $ 20 Billion |
Compound Annual Growth Rate | 31.8% |
Regions Covered | Global |